Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer
| Autor: | Woo Kyun Bae, Sang-Hee Cho, Ju Young Yun, Ik Joo Chung, Hyun Jeong Shim, Jun Eul Hwang |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Prognostic factor Palliative care medicine.medical_treatment Salvage treatment Salvage therapy Adenocarcinoma Young Adult Surgical oncology Risk Factors Stomach Neoplasms Signet ring cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Intestinal Neoplasms medicine Humans In patient Survival rate Aged Salvage Therapy Chemotherapy business.industry Palliative Care Gastroenterology General Medicine Middle Aged Advanced gastric cancer Prognosis medicine.disease Survival Rate Drug Resistance Neoplasm Third line chemotherapy Female Neoplasm Recurrence Local business Carcinoma Signet Ring Cell Progressive disease Follow-Up Studies |
| Zdroj: | Journal of Clinical Oncology. 29:e14613-e14613 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Almost all patients with advanced gastric cancer will eventually develop progressive disease after first-line chemotherapy. However, the role of subsequent salvage chemotherapy remains controversial. The purpose of this study was to evaluate prognostic factors for the survival of patients with advanced gastric cancer who received third-line chemotherapy.We reviewed 502 patients with advanced gastric cancer who received palliative chemotherapy at the Onocology Department of Hwasun Chonnam National University Hospital (2004-2008). Among them, 174 received third-line chemotherapy. To evaluate the clinicopathologic factors that affected overall survival, univariate and multivariate analyses were performed on the baseline factors before beginning third-line chemotherapy.Multivariate analysis found 4 prognostic factors affecting poor survival following third-line chemotherapy: performance status of 2-3 (hazard ratio [HR] 1.46, 95% confidence interval [CI] 1.06-2.02; P = 0.022), serum albumin level4 mg/dL (HR 1.82, 95% CI 1.32-2.53; P0.00), poor histologic type (HR 1.77, 95% CI 1.27-2.47; P = 0.001), and progression-free survival of2.7 months following second-line chemotherapy (HR 1.51, 95% CI 1.09-2.08; P = 0.012). A prognostic index was constructed, dividing patients into low- (0-1 factor), intermediate- (2 or 3 risk factors), or high- (4 risk factors) risk groups. Median survival times for each group were 11.8, 6.7, and 3.3 months, respectively (P0.00).This analysis suggests that some clinicopathologic factors might be helpful in identifying the subgroup of patients most likely to benefit from third-line chemotherapy for advanced gastric cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|